Preclinical safety study of a gemcitabine-controlled release polymer for locoregional administration in pancreatic cancer
There is a subpopulation of pancreatic tumor pluripotent cells with mechanisms of drug resistance that favor the locoregional recurrence and poor prognosis of the disease. In this work, the preclinical study of the safety of gemcitabine (GEM) impregnated in polymeric foams designed for intraoperativ...
| Autores: | , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Universidad de Castilla-La Mancha |
| Repositorio: | RUIdeRA. Repositorio Institucional de la UCLM |
| OAI Identifier: | oai:ruidera.uclm.es:10578/35838 |
| Acceso en línea: | https://doi.org/10.1016/j.jddst.2023.104843 https://hdl.handle.net/10578/35838 |
| Access Level: | acceso abierto |
| Palabra clave: | Gemcitabine Intraoperative administration Pancreatic cancer Supercritical CO2 foaming |
| Sumario: | There is a subpopulation of pancreatic tumor pluripotent cells with mechanisms of drug resistance that favor the locoregional recurrence and poor prognosis of the disease. In this work, the preclinical study of the safety of gemcitabine (GEM) impregnated in polymeric foams designed for intraoperative administration in pancreatic cancer (PC) is introduced. |
|---|